Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer-Reference-Cited by-同舟云学术

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

Published:2012-02-09 Issue:6 Volume:366 Page:520-529
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Baselga José,Campone Mario,Piccart Martine,Burris Howard A.,Rugo Hope S.,Sahmoud Tarek,Noguchi Shinzaburo,Gnant Michael,Pritchard Kathleen I.,Lebrun Fabienne,Beck J. Thaddeus,Ito Yoshinori,Yardley Denise,Deleu Ines,Perez Alejandra,Bachelot Thomas,Vittori Luc,Xu Zhiying,Mukhopadhyay Pabak,Lebwohl David,Hortobagyi Gabriel N.

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1109653

Cited by 2418 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adipocyte-conditioned medium induces tamoxifen resistance by activating PI3K/Akt/mTOR pathway in estrogen receptor-positive breast cancer cells;Biochimica et Biophysica Acta (BBA) - Molecular Cell Research;2024-10

2. Implications of obesity and insulin resistance for the treatment of oestrogen receptor-positive breast cancer;British Journal of Cancer;2024-09-09

3. Regulatory T cells: masterminds of immune equilibrium and future therapeutic innovations;Frontiers in Immunology;2024-09-03

4. Thymic epithelial tumor medical treatment: A narrative review;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

5. Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial;The Lancet Oncology;2024-09